Test drug RGT-419B for advanced ER+ HER2- breast cancer
Part of Cancer, Skin clinical trials.
This Phase 1 study tests a new drug (RGT-419B), given alone or with hormone (endocrine) therapy, in people with advanced ER-positive, HER2-negative breast cancer that has progressed after standard treatments. It looks mainly at safety and early signs of how well the treatment may work.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be age 18 or older.
- You must have ER-positive and HER2-negative breast cancer that cannot be removed by surgery (stage III) or has spread (stage IV).
- Your cancer must have at least one measurable spot that can be tracked on scans.
- Your cancer must have gotten worse after hormone (endocrine) therapy plus a CDK4/6 inhibitor, given for long enough (about 3 months in metastatic cancer, or about 6 months in earlier adjuvant use).
- You should have had no more than 1 prior chemotherapy treatment in the metastatic setting, and no more than 3 total hormone-therapy lines.
- Your general health should be good enough for study treatment (ECOG 0–1) and your organs (liver, kidneys, blood counts, etc.) must be able to handle treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called RGT-490 in patients with advanced solid tumors (cancers that have spread or cannot be removed by surgery) that have a specific genetic change called a PIK3CA mutation. The drug is designed to block a protein involved in cancer cell growth.
This trial tests a new treatment (GDC-4198) alone or with another drug (giredestrant) compared to a standard combination (abemaciclib and giredestrant) for people with advanced hormone receptor-positive, HER2-negative breast cancer that has progressed after previous treatments.
This trial tests a new oral drug, BTX-9341, for people with advanced or metastatic hormone receptor-positive, HER2-negative breast cancer who have already had certain treatments, including a CDK4/6 inhibitor. The goal is to see if it is safe and effective.
This trial tests a combination of targeted therapies (trastuzumab and pertuzumab) with chemotherapy (docetaxel) and an experimental drug (QL1706) given before surgery to shrink early or locally advanced HER2-positive breast cancer. It aims to see if this approach improves outcomes before definitive surgery.
This Phase 2 study tests a combination of immune-based treatments along with hormone (endocrine) therapy to slow or shrink advanced, hormone-receptor positive, HER2-negative breast cancer. You may be a candidate if your cancer has progressed after standard hormone-blocking medicines and you can start treatment with CDK4/6 medicine plus an aromatase inhibitor.
This Phase 1/2 study tests how well a new treatment combination (VS-6766, abemaciclib, and fulvestrant) works for metastatic or hard-to-remove breast cancer that is hormone-driven (ER/PR positive) and HER2 negative. It is mainly designed to find the safest dose and then see whether it can control the cancer after it has progressed on certain prior medicines.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.